Y Intercept Hong Kong Ltd Makes New Investment in Ocugen, Inc. $OCGN

Y Intercept Hong Kong Ltd purchased a new stake in shares of Ocugen, Inc. (NASDAQ:OCGN) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 343,557 shares of the company’s stock, valued at approximately $333,000. Y Intercept Hong Kong Ltd owned 0.12% of Ocugen as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Bank of New York Mellon Corp boosted its position in shares of Ocugen by 7.8% in the first quarter. Bank of New York Mellon Corp now owns 587,487 shares of the company’s stock valued at $415,000 after acquiring an additional 42,286 shares during the period. GSA Capital Partners LLP lifted its stake in Ocugen by 43.0% in the 1st quarter. GSA Capital Partners LLP now owns 1,638,033 shares of the company’s stock worth $1,157,000 after purchasing an additional 492,300 shares in the last quarter. Deutsche Bank AG lifted its stake in Ocugen by 3,799.2% in the 1st quarter. Deutsche Bank AG now owns 242,023 shares of the company’s stock worth $172,000 after purchasing an additional 235,816 shares in the last quarter. Invesco Ltd. boosted its holdings in Ocugen by 8.7% in the 1st quarter. Invesco Ltd. now owns 188,678 shares of the company’s stock valued at $133,000 after purchasing an additional 15,125 shares during the period. Finally, Nuveen LLC purchased a new position in shares of Ocugen during the 1st quarter valued at $535,000. 10.27% of the stock is owned by hedge funds and other institutional investors.

Ocugen Stock Performance

NASDAQ OCGN opened at $1.36 on Friday. Ocugen, Inc. has a 52-week low of $0.52 and a 52-week high of $1.90. The company has a fifty day moving average of $1.45 and a 200-day moving average of $1.12. The company has a market capitalization of $397.53 million, a P/E ratio of -6.80 and a beta of 4.15. The company has a debt-to-equity ratio of 9.18, a quick ratio of 1.83 and a current ratio of 1.83.

Ocugen (NASDAQ:OCGN) last released its earnings results on Wednesday, November 5th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). Ocugen had a negative net margin of 1,197.71% and a negative return on equity of 255.25%. The firm had revenue of $1.75 million during the quarter, compared to the consensus estimate of $0.44 million. As a group, equities research analysts predict that Ocugen, Inc. will post -0.2 EPS for the current fiscal year.

Analyst Ratings Changes

OCGN has been the topic of several research analyst reports. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 price target on shares of Ocugen in a report on Friday, September 19th. Weiss Ratings restated a “sell (e+)” rating on shares of Ocugen in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised Ocugen from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $7.00.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.